You are here


Founding Member

Susanne Schaffert, PhD

Chief Executive Officer, Novartis Oncology

Susanne Schaffert, Ph.D., has been CEO of Novartis Oncology since January 1, 2019. She is a member of the Executive Committee of Novartis. 

Ms. Schaffert was appointed Chairperson and President of Advanced Accelerator Applications when it was acquired by Novartis in January 2018, and will remain President until her successor is in place. She joined Novartis more than 20 years ago and served as Region Head, Novartis Oncology Europe, from 2012 to 2018. Prior to that, she was Head of Investor Relations for Novartis. She has also held other leadership positions during her career at Novartis, including Global Franchise Head for Immunology and Infectious Diseases, General Manager of Novartis Oncology in Northern and Central Europe, and General Manager of Novartis Oncology in Germany.  

Ms. Schaffert holds a doctorate in organic chemistry from the University of Erlangen in Germany. She is a member of the Board of Novartis AG Germany, and previously served on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2013


At Novartis Oncology, our mission is to discover new ways to improve and extend the lives of people with cancer. This starts with the health of our associates. Our accreditation with the CEO Cancer Gold Standard has provided us for the past 10 years with a valuable framework from which to structure our programs geared toward preventing cancer, providing support during the cancer journey, and encouraging the overall health and well-being of our associates.

— Susanne Schaffert, PhD

Gold Standard  Task Force Participation

Gold Standard Co-Chair, Accreditation Review Board Member & Member: Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical Officer

Global Gold Standard  Task Force Participation

Global Gold Standard Subcommittee Member: Dawn Aubel, EdD, MS, MPH, APNc, Medical Science Liaison Hematology

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Elizabeth Barrett, Chief Executive Officer, Novartis Oncology; Maya R. Said, Global Head, Oncology Policy and Market Access


Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit